H MRS) is a potential method to detect and quantify a boron neutron capture therapy 10 B-carrier compound, L-p-boronophenylalanine (BPA), in the brain. However, optimal positioning of MRS voxel to capture tissue with maximal BPA concentration can be challenging. Three dimensional proton magnetic resonance spectroscopic imaging (3D 1 H MRSI) provides spectral data covering a large spatial volume, which is a major advantage in detecting and quantifying BPA. BPA detection limit in phantom conditions was determined at 1.5 T using a 3D 1 H MRSI protocol with clinically acceptable nominal spatial resolution and duration. Quantification tests for aqueous phantom were performed using both single voxel MRS and 3D MRSI. In 3D MRSI, BPA detection limit was ~1.0 mM and BPA quantification accuracy was better than ±5%. The results suggest that MRSI would be a feasible method for in vivo BPA evaluation in clinical conditions.
INTRODUCTION
Boron neutron capture therapy (BNCT), is an evolving radiotherapy modality. Clinical trials have been conducted on the effectiveness of BNCT in tumors such as malignant glioma, melanoma and recurred head and neck carcinoma. [1] [2] [3] Despite of the clinical success in BNCT dose planning safety, some uncertainties still exist as in vivo methods to measure BPA concentration during the BNCT treatment are lacking.
In Finnish BNCT clinical trials, L-p-boronophenylalanine (BPA) has been used as the boron carrier.
2) Due to the poor water solubility of pure BPA at physiologic pH, BPAfructose complex (BPA-F) is used in the infusion. 4) The distribution of boron-10 in the tumor and surrounding healthy tissue greatly defines the absorbed tumor and healthy tissue doses in BNCT. 5) Therefore, a direct method to monitor boron accumulation in the patient's brain during or after the boron carrier infusion would be extremely beneficial. Currently, boron concentration estimates used in BNCT dose planning are usually calculated from whole blood samples using assumed tumor-to-blood and healthy brain-to-tumor boron concentration ratios. [6] [7] [8] Also pre-BNCT PET studies of 18 F-labeled BPA have been used to investigate the boron distribution. [9] [10] [11] In 1999, Zuo et al. reported that aromatic protons of BPA can be detected in the brain in vivo using proton magnetic resonance spectroscopy, 1 17, 18) The aim of the current work is to design an MRS protocol to detect BPA in a typical clinical environment, i.e. where only a normal clinical MRS/MRI equipment with a standard setup (sequences, coils) is available.
Previously, we have studied boron detection using single voxel MRS methods. [13] [14] [15] Here, we chose a PRESS sequence with a short echo time for BPA detection. The short echo time minimizes the effects of J-evolution on sig-nal intensities of BPA's strongly coupled aromatic protons. In our previous in vivo study, we encountered major problems in positioning of the MRS voxel; 15) the postoperative gross tumor volume (GTV) contains also the resection cavity with clotted blood that may significantly impair the quality of a single voxel spectrum. Also, necrotic areas in unoperated tumors and heterogeneous tumor regions (typical for gliomas) can hamper the single voxel positioning. These positioning problems can be readily circumvented using multidimensional 1 H MRS imaging (MRSI). Based on our initial phantom studies, 16) and also an animal studies by Bendel et al., 17,18) 1 H MRSI seems to be a feasible method for BPA detection in vivo. In the presented work, the applicability of the acquisition-weighted, short echo, three dimensional (3D) 1 H PRESS MRSI to detect aromatic protons of BPA was studied with phantoms.
MATERIAL AND METHODS
BPA detection limit was determined in phantom conditions at 1.5 T using a 17 min 3D acquisition-weighted 1 H PRESS MRSI protocol. Acquisition-weighted/elliptical scanning method with post-acquisition k-space filtering was used to reduce the measurement time significantly without losses in nominal spatial resolution or SNR. Also the feasibility of 3D 1 H MRSI for BPA quantification was studied. Quantification was done with an aqueous BPA-F/creatine phantom, using creatine as an internal concentration standard.
Phantoms and experimental setup
BPA-F solutions with BPA concentrations of 0.75, 1.0, 1.25, 1.5, 1.75, 2.25, 2.5 and 3.0 mM were prepared in 50 ml volumetric flasks. The 3.0 mM BPA solution also contained 10.1 mM creatine for quantification purposes. For the MRS measurement, the flask was placed in a 4 l spherical plastic phantom filled with 0.4% NaCl solution doped with MnCl2 (0.1 mM). In BNCT, the 10 B concentrations are typically expressed in units of ppm (parts per million i.e. mg/kgtissue) because the amount of boron in tumor tissue is responsible for success of BNCT. BPA concentration 3.0 mM used in the quantification study corresponds to 30 ppm 10 B concentration in aqueous solution. As comparison, a typical estimated tumor 10 B concentration during the first neutron irradiation field is approximately 50 ppm (calculated from measured blood concentration assuming tumor-toblood ratio 3.5:1).
2) It should be noted that in tissue, the relation 1 mM BPA equals 10 ppm 10 B, does not strictly hold and is only approximate because the precise relation between the two concentration units depends on the tissue density. To avoid any mix-up between MRS chemical shift unit and 10 B concentration, we will use mM as concentration unit in the following text.
Phantom measurements were performed using a 1.5 T clinical MRI scanner (Siemens Magnetom Sonata, Erlangen, Germany) and a standard receiver head coil. A PRESS sequence 19, 20) with CHESS water suppression scheme 21) was used for MRS/MRSI measurements. In our institution, repetition time (TR) of 1500 ms is commonly used in clinical MRS and MRSI protocols. Accordingly, this value was also used in BPA detection limit determination and quantification measurements. As noted in the previous studies, TR of 1500 ms is close to the optimal TR value (~1.3T 1 ) for BPA. 13, 14) Spectral post-processing and lineshape fitting were done using the standard software package of the MRI scanner (Siemens Syngo MMWP, VE23A).
Detection limit
For each phantom, 3D PRESS 1 H MRS imaging was performed using echo time (TE) of 30 ms, repetition time (TR) of 1500 ms and 2 averages. Field-of-view (FOV) of 16 × 16 × 12 cm 3 was covered with 16 × 16 × 8 phase encoding steps producing a nominal voxel size of 10 (RL) × 10 (AP) × 7.5 (SI) mm 3 (one-fold spatial zero filling in SI direction prior to Fourier transformation). The volume-of-interest (VOI) was 10 × 10 × 6 cm 3 , spectral bandwidth was 1000 Hz and the number of acquired complex points was 512. Weighted/elliptical k-space sampling was used and postacquisition k-space filtering with a Hamming filter (50%) was applied prior to Fourier transformation in spatial dimensions. The measurement time for the 1 H MRSI protocol was 17 minutes 9 seconds.
Zero filling from 512 to 1024 time domain data points and Hamming apodization with line broadening factor (LB) of 2.5 Hz were applied before the Fourier transformation in spectral dimensions. Signal-to-noise ratio (SNR) was determined from the voxel located at the midpoint of the BPA-F flask. The noise was determined as 2SD (standard deviation) from the 8-10 ppm region. Signal was determined as an amplitude of the BPA spectral peak located at 7.47 ppm. The detection limit was evaluated by visual inspection of the spectra (three independent viewers: MT, NL, SH). The criterion for a positive detection was the identification of the typical four-peak pattern of BPA's aromatic protons (SNR~3).
14)

T 1 measurements
The longitudinal relaxation time, T1, of creatine in aqueous phantom was measured for quantification purposes. 
Quantification and SNR comparison
The quantification of BPA was done for the 3.0 mM BPA-F phantom using both single voxel 1 1 H MRSI measurement was done using the protocol described previously in section Detection limit. The intensities of BPA aromatic protons and creatine signal were determined using Gaussian lineshape fitting. The intensities were corrected for T 1 -effects using T 1 -values of 935 ms 13) and 1500 ms for BPA and creatine, respectively. No corrections for T 2 -effects were performed as they were estimated to be minor due to the short TE. The SNR values for single voxel MRS and MRSI were measured.
RESULTS
The detection limit of ~1.0 mM was obtained for aromatic protons of BPA using a 17 min 3D PRESS 1 H MRSI protocol. The 3D 1 H MRSI spectra used in detection limit determination are presented in Fig. 1 . Results of BPA quantification using single voxel 1 H MRS and 3D 1 H MRSI and SNR H MRSI spectrum measured from the center of the BPA phantom is presented in Fig. 2. 
DISCUSSION
The measured 1.0 mM detection limit for BPA is relatively low compared to the values that were previously determined with single voxel MRS. 14) Using single voxel MRS, the BPA detection limit was 1. 14) The high SNR (and low detection limit) of the 3D MRSI compared to the single voxel MRS (Table 1) is most likely due to a larger actual voxel volume in 3D weighted sampling technique with 50% Hamming postacquisition k-space apodization. In MRSI, apodization is typically applied before Fourier transformation of k-space sampling points. This artificially improves point spread functions (PSF) by avoiding outer volume contamination due to the Gibbs artefact. Hamming filter reduces contamination of adjacent voxels, but at the same time causes a spread of the main maximum of PSF and consequently increases the actual voxel size. 22) A weighted sampling technique decreases the measurement time efficiently without SNR losses. 23, 24) The high SNR of acquisition-weighted MRSI is not only due to the larger actual voxel volume (compared to a conventional, fully-encoded MRSI) but also to the lower (negative) contamination of adjacent voxels. 23) Therefore, it is an efficient way to maximize the probability of detection of low concentration resonances. If acquisitionweighted MRSI (50% Hamming filter) is compared to the single voxel MRS, the difference in the actual voxel volume is remarkable. The SNR values in Table 1 . indicate that the SNR of MRSI (nominal voxel volume 10 × 10 × 7.5 mm 3 ) is close to the single voxel spectra with a nominal voxel size of 22 × 22 × 22 mm 3 (the line widths were approximately same for both single voxel and 3D MR spectrum, indicating comparable magnetic field homogeneity in both experiments). This data suggest that the actual voxel volume in the used 3D experiment is considerably larger than the nominal one. This is in line with the theory of weighted scanning-MRSI with Hamming k-space apodization and its impact on spatial resolution (and spreading of the PSF main peak). 23) These effects should be considered, if commonly used weighed/elliptical scanning-MRSI protocols are applied for radiotherapy treatment planning or surgical mapping purposes.
Single voxel MRS would be optimal for BPA detection if the location and distribution of BPA were well known. Using single voxel MRS, the spectral quality is usually better and thus the quantification can be more accurate compared to MRSI. However, because the exact location of tissue with BPA concentration maximum is actually unknown and the expected BPA concentration fairly low, we recommend the use of short echo, acquisition-weighted MSRI instead of a single voxel MRS. It would be ideal to first detect the location of BPA using MRSI and then measure the single voxel spectrum for quantification purposes. This is typically beyond the available time, as also single voxel MRS will necessitate a long accumulation time to detect small concentrations. These suggestions are made based on the measurements done at magnetic field strength of 1.5 T. At the higher field, the detection limit of BPA is lower and a single voxel MRS method could be sufficient. In addition, if conventionally k-space sampled 3D MRSI techniques are used, the detection limit of BPA is likely to be larger and therefore the detection of low BPA concentrations in a reasonable measurement time can be difficult. The optimal time point for MRSI in the BNCT procedure would be soon after the boron carrier infusion. This indicates that MRSI could have potential in actual dose planning of BNCT treatment. However, on-going clinical research protocol does not allow the suggested MRSI study before the treatment. In future studies this option could be included in the study protocols (in addition, PET-studies with 18 F-labeled BPA will also be included as an option in our future protocols). To perform post-BNCT MRSI study, patient logistics between BNCT and MRS sites must be fast enough in order not to allow too much time for BPA concentration to go below detectable level. 15) In principle, also repeated MRSI studies performed in course of the infusion would be useful for dose planning to further explore the spatial-temporal characteristics of the BPA bio-distribution. In practice, however, repeated MRSI scans during relatively massive BPA-infusion can be intolerable to a patient and therefore cannot be easily performed. Obviously, the same restrictions would apply for an extra, pre-treatment infusion solely for MRSI study. Such extra infusion is not feasible due to extra patient stress.
Recently, good responses of head and neck cancer to BNCT have been reported. 25, 26) This may be due to the attainable high BPA concentration within tumor tissue. This, in principle, should facilitate BPA detection with MRSI. However, the heterogeneity of tissue, air-tissue-interfaces, air cavities etc make the use of MRS/MRSI in these target tissues/regions extremely challenging. 15) Therefore, in the head and neck area, PET detection of 18 F-labeled BPA might be more beneficial. The quantification accuracy of 3D 1 H MRSI in phantoms is good (Table1) suggesting that 3D MRSI is reasonable method to estimate BPA concentrations in vivo (provided that MRSI is done at such time point when BPA concentration in tumor is sufficient for BPA quantification).
To summarize, 3D MRSI is a practical method to detect and quantify BPA. Using an acquisition weighted MRSI, it is possible to detect BPA resonances in a reasonable measurement time. 3D method also avoids voxel positioning problems related to finding voxel location capable of giving representative estimation of tumor BPA content and also resulting in a good quality spectrum. In addition, 3D method can provide data from surrounding/contralateral healthy tissue that can be used to estimate tumor BPA concentrations.
